1- fold increases in caspase-3/7 enzyme activity (figure 5) (p < 0.05). Figure 5 Percentage KPT-330 cost changes in caspase 3/7 enzyme activity in ATRA and zoledronic acid combination or any agent alone exposed this website OVCAR-3 and MDAH-2774 cells (p < 0.05). Oligoarray and RT-PCR analyses of apoptosis-related genes in OVCAR-3 cells by the combination treatment We used apoptosis specific oligoarray to examine the changes in expression levels of mRNAs of the apoptosis related genes in response to ATRA and zoledronic acid

treatment in OVCAR-3 cells as compared to untreated controls. Based on the IC50 results of each agent in OVCAR-3 and MDAH-2774 cells, OVCAR-3 cancer cells were found to be more chemorefractory. Thus, we have chosen OVCAR-3 cell line to study the mechanistic rationale of apoptosis with this RAD001 in vivo combination. For this experiment, we have applied the doses of 80 nM ATRA and 5 μM zoledronic acid for oligoarray experiments. These doses were chosen because they are much more less than the IC50 doses of each agent and weak inducers of apoptosis in OVCAR-3 cells, and thus letting the oligoarray results not to be

shaded by strong apoptotic effect. Three repeated experiments were carried out and the results showed that there were 6.8-, 4.9- and 4.8- fold increase in TNFRSF 1A, 10B and TNFRSF 1A-associated death domain (TRADD) mRNA levels in OVCAR-3 cells when treated with combination

of ATRA and zoledronic acid, as compared to any agent alone (table 2) (p < 0.05). Moreover, proapoptotic members of Bcl-2 family (i.e BNIP3) were also shown to be induced whereas the antiapoptotic members of the same family (i.e BCL2L1, BCL2L12, BCL2L13) were inhibited by the treatment. Table 2 Fold changes in apoptosis related genes by OligoArray in OVCAR-3 cells   Fold Change in OVCAR-3 cells Gene Symbol ATRA (80 nM) Zoledronic Astemizole Acid (5 μM) Combination BCL2L-1 (BCL-xL) -1.8 -2.1 -4.0 BCL2L12 -1.3 -1.5 -3.1 BCL2L13 -1.3 -2.6 -7.0 BNIP3 +1.9 +2.4 +3.9 TNFRSF1A +1.5 +3.6 +6.8 TNFRSF10B +1.6 +3.4 +4.9 TRADD +1.3 +1.2 +4.8 CASP4 +1.2 +1.4 +3.2 MCL-1 -2.2 -1.6 -3.3 BAG3 -1.0 -1.0 -3.1 LTBR -1.4 +2.5 -4.9 *p < 0.05 In contrary, mRNA levels of lymphotoxin beta receptor (LTBR), myeloid cell leukemia-1 (MCL-1) and BCL2-associated athanogene 3 (BAG3) were reduced by the combination treatment by 4.9-, 3.3- and 3.1- fold decrease, respectively, as compared to each of the single agent (table 2) (p < 0.05). The genes mentioned above are responsible for resistance to apoptosis in many types of human cancer cells, thus the reduction of mRNA levels of these genes point out that the synergistic combination treatment is effective on inducing apoptosis in OVCAR-3 cells.